What You Should Know:
- One year ago, President Joe Biden and First Lady Jill Biden reignited the Cancer Moonshot, setting an ambitious, achievable goal: to reduce the death rate from cancer by at least 50 percent over the next 25 years, and improve the experience of people and families living with and surviving cancer, ultimately ending cancer as we know it today.
- The Cancer Moonshot has spurred tremendous action across the federal government and from the public and private
Read More
lung
Is AI-Assisted Lung Cancer Diagnosis Right For Your Hospital?
Lung cancer is the leading cause of cancer deaths worldwide, with approximately 1.8 million people dying from this disease each year. Most patients are diagnosed after symptoms have appeared and the disease has progressed to an advanced stage (Stage III or IV), which explains the current worldwide five-year survival rate of just 20 percent. In contrast, the survival rate for small lung tumors that are treated at Stage 1A is as high as 90 percent. This significant difference highlights a critical
Read More
Liver Cancer Awareness – Here’s What You Need to Know in 2023
By the end of 2022, nearly 42,00 new cases of primary liver cancer will be diagnosed in the United States. In fact, liver cancer incidence rates have more than tripled since 1980, marking an increased need for better detection and diagnosis.
We might not talk about liver cancer as much as we do breast or lung cancer, but it’s a real threat to millions of Americans – and we need to continue spreading awareness.
Early detection is especially critical in treating liver cancer.
Read More
AI Improving the Patient Experience of Cancer Care
For cancer patients and their loved ones, days, weeks, and months matter. In fact, anyone who has waited anxiously for test results or a treatment regimen to begin can attest that hours, or even minutes, will drag on with emotional heaviness. From a clinical standpoint as well, time to treatment significantly impacts outcomes. All suspected cancers should be ruled out or confirmed with a diagnosis so treatment can begin as soon as possible. Similarly, patients with incidental findings—masses or
Read More
Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies
What You Should Know:
- Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. IBF and Peregrine Ventures led the round, with participation from aMoon Fund and other existing investors.
- The funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of
Read More
What Has COVID Ever Done For Us? Here 9 Examples
The early 2020s will be studied by historians as a time of global uncertainty when an unknown pathogen caused a public health emergency that brought the world to the brink.
It may also be remembered as a time of unparalleled cooperation and advancement in technologies, prompted by the Covid pandemic, that provided enduring benefits for generations to come.
Just as the two world wars of the 20th Century were the deadliest and most attritional in history, they also triggered developments in
Read More
Oatmeal Health Brings AI-Powered Lung Cancer Screening to The Clinic in Oklahoma
What You Should Know:
- Central Oklahoma Family Medical Center FQHC (The Clinic) has selected Oatmeal Health, a veteran-owned Patient Success Service to bring tech-enabled lung cancer screenings to their patients.
- As part of the partnership, Oatmeal Health will provide white-glove, concierge service, offering our support without FQHC’s shouldering the burden or cost.
Tech-Enabled Lung Cancer Screening
Currently, lung screening rates hover at around 4 percent
Read More
The Gains and Pains of Using AI in the Pharmaceutical Industry
The costs for drug discovery and development are skyrocketing, but AI (artificial intelligence) is introducing new efficiencies to help find effective treatments faster.
A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million. Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most
Read More
ChristianaCare Spins Out New Gene Editing Company, CorriXR Therapeutics
What You Should Know:
- ChristianaCare recently announced it has spun out its first commercial biotechnology private startup company, named CorriXR Therapeutics. The company will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute uniquely positions it to research and develop
Read More
SEQSTER and PatientsLikeMe Launch National Rare Disease Study
What You Should Know:
- PatientsLikeMe and SEQSTER announced a collaboration to launch one of the first rare-disease studies focused on Alpha-1 Antitrypsin Deficiency (AATD) - a rare genetic condition occurring in approximately 1/3500 people.
- AATD is a rare genetic condition occurring in approximately 1/3500 people. It is characterized by low levels of the alpha-1 antitrypsin protein, leading AATD patients to be very susceptible to lung and/or
Read More
